Moderna (MRNA) has released an update.
Moderna’s RSV vaccine, mRESVIA, has received a positive opinion from the EMA’s CHMP, signaling a step closer to marketing authorization in the EU for adults over 60. The vaccine has shown high efficacy in preventing lower respiratory tract disease caused by RSV, as evidenced by Phase 3 clinical trials. This development marks another significant achievement for Moderna’s mRNA technology platform, following the success of their COVID-19 vaccines.
For further insights into MRNA stock, check out TipRanks’ Stock Analysis page.
